CClinicalTrials.gg
Status unknownNCT04338880Updated Apr 8, 2020

Academic Performance and Refractive Error

An observational study in Refractive Errors, sponsored by Sun Yat-sen University. Status unknown at 1 site in China. Open to participants aged 6 Years to 15 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Sun Yat-sen University · Observational

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
6 Years to 15 Years
Sex
All
01

Study summary

Refractive errors constitute the leading cause of visual disability worldwide and that myopia progresses dramatically when students reach school age. Studies from different countries have reported inconsistent associations between educational outcomes and refractive errors. Therefore, our study aimed to assess the associations of high academic performance with ametropia prevalence and myopia progression in Chinese schoolchildren base on a multicohort observational design.

02

Conditions studied

  • Refractive Errors

Browse trials for

03

In context

Refractive Errors

413 studies on the registry are indexed under Refractive Errors; 62 are open to participants now.

This study's planned enrollment of 10,000 is above the median of 150 across 107 observational studies indexed under Refractive Errors.

Browse Refractive Errors studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 15 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

A prospective multicohort observational study of schoolchildren who studied in the 1st to 9th grades was performed.

Inclusion criteria

  • schoolchildren in the 1st to 9th grades

Exclusion criteria

Exclusion Criteria:

  • schoolchildren unwilling to participate
  • had a history of wearing rigid contact lenses, medical treatment or diseases that could cause poor vision or negatively affect the academic outcomes
  • with unreliable auto-refraction values
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. the changes of spherical equivalent refractive (RSE)

    A multi-linear regression was used.

    Time frame: up to 3 years

07

Study locations

1 of 1 sites recruiting
  • Zhognshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04338880
Lead sponsor
Sun Yat-sen University
Responsible party
Haotian Lin (Principal Investigator, Sun Yat-sen University) — Principal investigator
First posted
Apr 8, 2020
Start date
Sep 1, 2016
Primary completion
Jun 30, 2019
Completion
Dec 1, 2020 (estimated)
Last update
Apr 8, 2020

Study contacts

Yahan Yang, M.D.
Contact
yah.yang39@hotmail.com
+8615521013933

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion